Target coverage and dose to OAR
The target metrics and dose achieved to OAR are displayed in Table Summary of plan quality parameters evaluated for all Halcyon plans compared to clinical TrueBeam plans for APBI patients.
An example patient from the benchmarking cohort representing the typical findings of our validation study is illustrated in Figure Left: Demonstration of the benchmarked hypofractionated clinical TrueBeam plan (26 Gy in 5‐fraction, daily). Right: the corresponding Halcyon APBI plan for benchmarking the Fast‐Forward trial at our institute. Center: DVH for TrueBeam (squares) and Halcyon (triangles). Red and pink contours are GTV and PTV respectively, achieved similar and highly conformal and homogeneous dose distributions on both platforms. A similar, yet tighter, 50% isodose line (blue) on Halcyon RDS was observed. For similar target coverage, similar contralateral breast dose (yellow) and heart dose (blue) were observed, yet absolute 3% lower ipsilateral lung V8Gy (cyan) was found on Halcyon.